HK1070391A1 - Methods and compositions relating to hpv-associated pre-cancerous and cancerous growths, including cin - Google Patents

Methods and compositions relating to hpv-associated pre-cancerous and cancerous growths, including cin

Info

Publication number
HK1070391A1
HK1070391A1 HK05102959A HK05102959A HK1070391A1 HK 1070391 A1 HK1070391 A1 HK 1070391A1 HK 05102959 A HK05102959 A HK 05102959A HK 05102959 A HK05102959 A HK 05102959A HK 1070391 A1 HK1070391 A1 HK 1070391A1
Authority
HK
Hong Kong
Prior art keywords
cancerous
hpv
methods
compositions relating
associated pre
Prior art date
Application number
HK05102959A
Other languages
English (en)
Inventor
Jagannadha K Sastry
Guillermo Tortolero-Luna
Michele Follen
Original Assignee
Univ Texas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Texas filed Critical Univ Texas
Publication of HK1070391A1 publication Critical patent/HK1070391A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/571—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses for venereal disease, e.g. syphilis, gonorrhoea
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/01—DNA viruses
    • G01N2333/025—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Virology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
HK05102959A 2001-07-20 2005-04-08 Methods and compositions relating to hpv-associated pre-cancerous and cancerous growths, including cin HK1070391A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30680901P 2001-07-20 2001-07-20
PCT/US2002/023198 WO2003008649A1 (en) 2001-07-20 2002-07-19 Methods and compositions relating to hpv-associated pre-cancerous and cancerous growths, including cin

Publications (1)

Publication Number Publication Date
HK1070391A1 true HK1070391A1 (en) 2005-08-19

Family

ID=23186942

Family Applications (1)

Application Number Title Priority Date Filing Date
HK05102959A HK1070391A1 (en) 2001-07-20 2005-04-08 Methods and compositions relating to hpv-associated pre-cancerous and cancerous growths, including cin

Country Status (6)

Country Link
US (2) US7410758B2 (zh)
EP (1) EP1417353A4 (zh)
JP (1) JP2004535816A (zh)
CN (1) CN100335121C (zh)
HK (1) HK1070391A1 (zh)
WO (1) WO2003008649A1 (zh)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL105554A (en) * 1992-05-05 1999-08-17 Univ Leiden Peptides of human papillomavirus for use in preparations elicit a human T cell response
US8128922B2 (en) * 1999-10-20 2012-03-06 Johns Hopkins University Superior molecular vaccine linking the translocation domain of a bacterial toxin to an antigen
AU2001278117A1 (en) * 2000-08-03 2002-02-18 Johns Hopkins University Molecular vaccine linking an endoplasmic reticulum chaperone polypeptide to an antigen
AU2001291162A1 (en) 2000-09-25 2002-04-08 Regents Of The University Of Michigan Production of viral vectors
GB0307403D0 (en) 2003-03-31 2003-05-07 Medical Res Council Selection by compartmentalised screening
US20060078893A1 (en) 2004-10-12 2006-04-13 Medical Research Council Compartmentalised combinatorial chemistry by microfluidic control
GB0307428D0 (en) 2003-03-31 2003-05-07 Medical Res Council Compartmentalised combinatorial chemistry
WO2004098526A2 (en) * 2003-05-05 2004-11-18 Johns Hopkins University Anti-cancer dna vaccine employing plasmids encoding signal sequence, mutant oncoprotein antigen, and heat shock protein
US20050221339A1 (en) 2004-03-31 2005-10-06 Medical Research Council Harvard University Compartmentalised screening by microfluidic control
US7968287B2 (en) 2004-10-08 2011-06-28 Medical Research Council Harvard University In vitro evolution in microfluidic systems
WO2006052822A2 (en) * 2004-11-05 2006-05-18 Cytolution, Inc. Methods and devices for screening cervical cancer
CA2594040A1 (en) 2005-01-06 2006-07-13 The Johns Hopkins University Rna interference that blocks expression of pro-apoptotic proteins potentiates immunity induced by dna and transfected dendritic cell vaccines
EP1846026A4 (en) * 2005-01-26 2008-07-02 Univ Johns Hopkins ANTICANCER DNA VACCINE USING PLASMID CODING ANTIGEN AND CALRETICULIN SUCH AS MUTANT ONCOPROTEINS
US8252893B2 (en) * 2005-01-31 2012-08-28 Board Of Trustees Of The University Of Arkansas CD8 T cell epitopes in HPV 16 E6 and E7 proteins and uses thereof
CA2636855C (en) 2006-01-11 2016-09-27 Raindance Technologies, Inc. Microfluidic devices and methods of use in the formation and control of nanoreactors
EP3031918B1 (en) 2006-05-11 2018-03-14 Raindance Technologies Inc. Microfluidic devices
US9562837B2 (en) 2006-05-11 2017-02-07 Raindance Technologies, Inc. Systems for handling microfludic droplets
WO2008021123A1 (en) 2006-08-07 2008-02-21 President And Fellows Of Harvard College Fluorocarbon emulsion stabilizing surfactants
WO2008024844A2 (en) * 2006-08-22 2008-02-28 The Johns Hopkins University Anticancer combination therapies
WO2008097559A2 (en) 2007-02-06 2008-08-14 Brandeis University Manipulation of fluids and reactions in microfluidic systems
US9085638B2 (en) 2007-03-07 2015-07-21 The Johns Hopkins University DNA vaccine enhancement with MHC class II activators
US20080260765A1 (en) * 2007-03-15 2008-10-23 Johns Hopkins University HPV DNA Vaccines and Methods of Use Thereof
WO2008130623A1 (en) 2007-04-19 2008-10-30 Brandeis University Manipulation of fluids, fluid components and reactions in microfluidic systems
AU2013205259B2 (en) * 2007-05-31 2015-06-11 Isa Pharmaceuticals B.V. HPV epitopes targeted by T cells infiltrating cervical malignancies for use in vaccines
AU2015213420B2 (en) * 2007-05-31 2017-02-16 Isa Pharmaceuticals B.V. HPV epitopes targeted by T cells infiltrating cervical malignancies for use in vaccines
JP6035503B2 (ja) * 2007-05-31 2016-11-30 アカデミシュ ジーケンハウス ライデン ハー．オー．デー．エン． ルムク ワクチンで使用するための、子宮頸部悪性腫瘍に浸潤するｔ細胞によって標的とされるｈｐｖエピトープ
US9562075B2 (en) * 2007-05-31 2017-02-07 Academisch Ziekenhuis Leiden H.O.D.N. Lumc Intradermal HPV peptide vaccination
EP3539567A1 (en) 2007-07-02 2019-09-18 Etubics Corporation Methods and compositions for producing an adenovirus vector for use with multiple vaccinations
US20090285861A1 (en) * 2008-04-17 2009-11-19 Tzyy-Choou Wu Tumor cell-based cancer immunotherapeutic compositions and methods
EP2315629B1 (en) 2008-07-18 2021-12-15 Bio-Rad Laboratories, Inc. Droplet libraries
WO2010111231A1 (en) 2009-03-23 2010-09-30 Raindance Technologies, Inc. Manipulation of microfluidic droplets
CN106957361A (zh) * 2009-04-20 2017-07-18 阿波维塔公司 Hpv的e6蛋白的特异性抗体及其应用
DK2452194T3 (en) * 2009-07-10 2015-11-30 Transgene Sa Biomarker PATIENT SELECTION AND RELATED PRACTICES
US10520500B2 (en) 2009-10-09 2019-12-31 Abdeslam El Harrak Labelled silica-based nanomaterial with enhanced properties and uses thereof
EP2517025B1 (en) 2009-12-23 2019-11-27 Bio-Rad Laboratories, Inc. Methods for reducing the exchange of molecules between droplets
US9366632B2 (en) 2010-02-12 2016-06-14 Raindance Technologies, Inc. Digital analyte analysis
US9399797B2 (en) 2010-02-12 2016-07-26 Raindance Technologies, Inc. Digital analyte analysis
US10351905B2 (en) 2010-02-12 2019-07-16 Bio-Rad Laboratories, Inc. Digital analyte analysis
CA2789425C (en) 2010-02-12 2020-04-28 Raindance Technologies, Inc. Digital analyte analysis with polymerase error correction
EP2558116B2 (de) 2010-04-16 2020-01-08 General Vectors GmbH Mittel zur lokalen behandlung von zervixdysplasien
US9562897B2 (en) 2010-09-30 2017-02-07 Raindance Technologies, Inc. Sandwich assays in droplets
CN102058874A (zh) * 2010-12-30 2011-05-18 重庆大学 一种治疗人乳头瘤病毒16型引发的肿瘤的多肽疫苗
EP2673614B1 (en) 2011-02-11 2018-08-01 Raindance Technologies, Inc. Method for forming mixed droplets
US9150852B2 (en) 2011-02-18 2015-10-06 Raindance Technologies, Inc. Compositions and methods for molecular labeling
EP2714970B1 (en) 2011-06-02 2017-04-19 Raindance Technologies, Inc. Enzyme quantification
US8841071B2 (en) 2011-06-02 2014-09-23 Raindance Technologies, Inc. Sample multiplexing
CN102279257B (zh) * 2011-06-27 2014-02-19 刘永庆 一种用于诊断人或动物的免疫相关性疾病的试剂盒
US8658430B2 (en) 2011-07-20 2014-02-25 Raindance Technologies, Inc. Manipulating droplet size
WO2013120089A1 (en) 2012-02-10 2013-08-15 Raindance Technologies, Inc. Molecular diagnostic screening assay
EP3524693A1 (en) 2012-04-30 2019-08-14 Raindance Technologies, Inc. Digital analyte analysis
US9605276B2 (en) 2012-08-24 2017-03-28 Etubics Corporation Replication defective adenovirus vector in vaccination
WO2014172288A2 (en) 2013-04-19 2014-10-23 Raindance Technologies, Inc. Digital analyte analysis
CN105393121B (zh) * 2013-04-29 2018-04-24 阿珀吉尼科斯股份公司 诊断癌症的方法
KR102004335B1 (ko) * 2013-09-26 2019-07-26 파이브3 제노믹스, 엘엘씨 바이러스-연관 종양을 위한 시스템, 방법, 및 조성물
US11901041B2 (en) 2013-10-04 2024-02-13 Bio-Rad Laboratories, Inc. Digital analysis of nucleic acid modification
US9944977B2 (en) 2013-12-12 2018-04-17 Raindance Technologies, Inc. Distinguishing rare variations in a nucleic acid sequence from a sample
US11193176B2 (en) 2013-12-31 2021-12-07 Bio-Rad Laboratories, Inc. Method for detecting and quantifying latent retroviral RNA species
WO2015165973A1 (en) 2014-04-29 2015-11-05 Apogenix Gmbh Diagnostic anti-cd95l antibody
AU2015317692A1 (en) 2014-09-17 2017-04-06 Hologic, Inc. Method of partial lysis and assay
EP3037103A1 (en) * 2014-12-23 2016-06-29 Genticel Immunotherapeutic vaccine comprising E7 proteins of HPV16 and HPV18 fused with CyaA, for use in subjects infected with HPV
EP3256140B1 (en) 2015-01-09 2020-04-01 Etubics Corporation Compositions for ebola virus vaccination
JP6647315B2 (ja) 2015-01-09 2020-02-14 イーチュービクス コーポレイション 組み合わせ免疫療法のための方法および組成物
US11149087B2 (en) 2015-04-20 2021-10-19 Etubics Corporation Methods and compositions for combination immunotherapy
WO2017015504A1 (en) 2015-07-21 2017-01-26 Scheibel Steven Frederick Treatment and prevention of anal conditions
US10647981B1 (en) 2015-09-08 2020-05-12 Bio-Rad Laboratories, Inc. Nucleic acid library generation methods and compositions
CN107383176A (zh) * 2017-05-10 2017-11-24 于学杰 用于对汉滩病毒和汉城病毒引起的肾综合征出血热分型的多肽
US10998178B2 (en) 2017-08-28 2021-05-04 Purdue Research Foundation Systems and methods for sample analysis using swabs
WO2020112720A1 (en) * 2018-11-28 2020-06-04 The General Hospital Corporation T cell-directed anti-cancer vaccines against commensal viruses
CN115236251A (zh) * 2022-07-08 2022-10-25 大连理工大学 一种用于宫颈癌诊断的评价指标

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5876922A (en) 1985-07-31 1999-03-02 Institute Pasteur Papillomavirus probe and a process for in vitro diagnosis of papillomavirus infections
JP2791685B2 (ja) 1989-06-08 1998-08-27 寳酒造株式会社 パピローマウイルスの検出方法
DE4009851A1 (de) * 1990-03-23 1991-09-26 Siemens Ag Kurzschluss- und buerstenabhebevorrichtung fuer asynchronmotoren mit schleifringlaeufer
FR2670797A1 (fr) * 1990-12-20 1992-06-26 Pasteur Institut Sequences d'adn determinees derivees du genome du papillomavirus hpv39, application de ces sequences au diagnostic in vitro d'infection par ce papillomavirus, et a la production de composition immunogene.
US6258576B1 (en) 1996-06-19 2001-07-10 Board Of Regents, The University Of Texas System Diagnostic method and apparatus for cervical squamous intraepithelial lesions in vitro and in vivo using fluorescence spectroscopy
US6135965A (en) 1996-12-02 2000-10-24 Board Of Regents, The University Of Texas System Spectroscopic detection of cervical pre-cancer using radial basis function networks

Also Published As

Publication number Publication date
US20050048467A1 (en) 2005-03-03
WO2003008649A1 (en) 2003-01-30
EP1417353A1 (en) 2004-05-12
US20090053296A1 (en) 2009-02-26
US7659071B2 (en) 2010-02-09
CN100335121C (zh) 2007-09-05
EP1417353A4 (en) 2005-08-03
JP2004535816A (ja) 2004-12-02
US7410758B2 (en) 2008-08-12
CN1556863A (zh) 2004-12-22

Similar Documents

Publication Publication Date Title
HK1070391A1 (en) Methods and compositions relating to hpv-associated pre-cancerous and cancerous growths, including cin
AU2003253217A1 (en) Composition for heart disease, method to prepare same and uses thereof
AU2002217226A1 (en) Methanesulphonamido-benzofuran, preparation method and use thereof as synthesis intermediate
AU2002237124B2 (en) Compositions and methods relating to osteoarthritis
AU2002311903A1 (en) Evaluation of ultraviolet radiation damage to skin using new genemarkers, methods and compositions related thereto
AU2003239568A1 (en) Pyrrolotriazinone compounds and their use to treat diseases
HK1074446A1 (en) 3-phenyl substituted pyridoindolone, preparation and therapeutic use thereof
AU2002366888A1 (en) Varying segment sizes to increase security
WO2005110009A8 (en) COMPOSITIONS AND METHODS RELATING TO TSP-30a, b, c AND d
AU2003251920A1 (en) Iron sequestration or elimination to reduce neurodegeneration or parkinsons disease progression
AU2001286810A1 (en) Compositions and methods relating to lung specific genes
AU2002239739A1 (en) Compositions, methods and kits relating to remodelin
AU2003293765A1 (en) Novel skin lightening agents, compositions and methods
AU2002360531A1 (en) Methods and compositions to treat cardiovascular disease using 1419, 58765 and 2201
AU2002330926A1 (en) Methods and compositions useful for bryophyte remediation to improve forest health and growth
AU2002322573A1 (en) Methods and compositions relating to hpv-associated pre-cancerous and cancerous growths, including cin
EP1414934B8 (en) Improvements relating to colour-safe fabric treatment compositions
GB2361386B (en) Improvements in or relating to wireless LAN`s
AU2001277937A1 (en) Compositions and methods relating to lung specific genes
WO2002083858A8 (en) Methods to inhibit viral replication
AU2003280544A1 (en) A special kind of indole compounds, their preparation, and their use in treatment and prevention of those disease such as cancer
AU2002360343A1 (en) Methods and compositions to treat cardiovascular disease using 139, 258, 1261, 1486, 2398, 2414, 7660, 8587, 10183, 10550, 12680, 17921, 32248, 60489 or 93804
AU2002242942A1 (en) 3-0-'alfa-l-rhamnopyranosyl- (1-2) -alpha-l-rhamnopyranosyl- (1-4) -3beta-d-glucopyranosyl!-25 (s) -spirost an-3beta-ol, process for its isolation, and its use as immunomodulator
GB0119526D0 (en) Easy to wear/remove underpants
AU2001289135A1 (en) Techniques to implement one-dimensional compression

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20110719